Compare SMHI & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SMHI | MDXH |
|---|---|---|
| Founded | 1989 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Marine Transportation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.4M | 167.8M |
| IPO Year | N/A | 2021 |
| Metric | SMHI | MDXH |
|---|---|---|
| Price | $6.00 | $3.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 110.6K | ★ 114.5K |
| Earning Date | 10-29-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $245,311,000.00 | $103,069,000.00 |
| Revenue This Year | N/A | $23.34 |
| Revenue Next Year | $8.81 | $22.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 21.68 |
| 52 Week Low | $3.63 | $1.35 |
| 52 Week High | $7.88 | $5.33 |
| Indicator | SMHI | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 34.37 | 50.37 |
| Support Level | $6.05 | $3.20 |
| Resistance Level | $6.39 | $3.58 |
| Average True Range (ATR) | 0.33 | 0.18 |
| MACD | -0.12 | 0.04 |
| Stochastic Oscillator | 16.28 | 85.42 |
Seacor Marine Holdings Inc provides marine and support transportation services to offshore energy facilities globally. The company operates and manages a diverse fleet of offshore support vessels that deliver cargo and personnel to offshore installations, including wind farms, handle anchors, and mooring equipment for offshore rigs and platforms. Its geographical segment includes the United States (Gulf of Mexico), Africa and Europe, Middle East and Asia, and Latin America.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.